ClinicalTrials.Veeva

Menu

Investigation of Female Reproductive Hormone Dynamics During Adolescence

Mass General Brigham logo

Mass General Brigham

Status and phase

Completed
Early Phase 1

Conditions

Menstruation Disturbances

Treatments

Drug: transdermal estradiol
Drug: micronized progesterone

Study type

Interventional

Funder types

Other

Identifiers

NCT02486757
2013P-000513

Details and patient eligibility

About

Irregular menstrual cycles are common in girls for several years after their first menstrual period. The cause of abnormal menstrual cycles during this time is not well-understood. The purpose of this study is to: 1) monitor girls during a menstrual cycle (with blood and urine sampling and serial pelvic ultrasounds) to identify those girls who do not ovulate (release of an egg from the ovary), and 2) determine whether cycles can be corrected by treating girls with a short course of low-dose estrogen and progesterone.

Enrollment

9 patients

Sex

Female

Ages

12 to 16 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • no more than 3 ½ years postmenarchal

Exclusion criteria

  • Subjects currently on or previously treated with medications that may affect reproductive hormones (eg birth control pills).
  • Subjects with severe acne or hirsutism
  • Subjects who exercise excessively (running > 20 miles/week or its equivalent)
  • Subjects with any of the following medical conditions: diabetes, hypertension, hyperlipidemia, valvular heart disease, lupus, rheumatoid arthritis, migraine headaches with aura, undiagnosed breast mass, inflammatory bowel disease, gallbladder disease, sickle cell disease, or thrombophilia.
  • Current smoker
  • History of deep venous thrombosis or pulmonary embolism in subject or first-degree relative

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

9 participants in 1 patient group

Interventional
Experimental group
Description:
estradiol 50 mcg transdermal patch x 7 days oral micronized progesterone 0.5 mg/kg/dose TID x 7 days
Treatment:
Drug: micronized progesterone
Drug: transdermal estradiol

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems